ArticleThe Journal of antimicrobial chemotherapy2020
Madurella mycetomatis, the main causative agent of eumycetoma, is highly susceptible to olorofim.
Article in The Journal of antimicrobial chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Eumycetoma causative agents: A systematic review to inform the World Health Organization priority list of fungal pathogens.Medical mycology · 2024Pooled it
- Olorofim in combination with azole antifungals: results from the Phase 2 salvage therapy study.The Journal of antimicrobial chemotherapy · 2026Trial
- Comment on: Antagonistic in vitro interaction between olorofim and voriconazole against Aspergillus fumigatus.The Journal of antimicrobial chemotherapy · 2026Article
- Antagonistic interaction between posaconazole and olorofim in a murine model of invasive pulmonary aspergillosis.The Journal of antimicrobial chemotherapy · 2025Article
- In vitro evaluation of olorofim and antifungal combinations against Aspergillus and Candida species.The Journal of antimicrobial chemotherapy · 2025Article
- Dematiaceous Molds.Infectious disease clinics of North America · 2025Review
- Review of the novel antifungal drug olorofim (F901318).BMC infectious diseases · 2024Review
- The performance and costs of XTT, resazurin, MTS and luciferin as viability dyes in in vitro susceptibility testing of Madurella mycetomatis.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2024Article
- An updated list of eumycetoma causative agents and their differences in grain formation and treatment response.Clinical microbiology reviews · 2024Review
- The Role of Olorofim in the Treatment of Filamentous Fungal Infections: A Review of In Vitro and In Vivo Studies.Journal of fungi (Basel, Switzerland) · 2024Review
- Sandalwood Oils of Different Origins Are Active In Vitro againstMolecules (Basel, Switzerland) · 2024Article
- Diagnostic capacities and treatment practices on implantation mycoses: Results from the 2022 WHO global online survey.PLoS neglected tropical diseases · 2023Article
- Characterisation of putative class 1A DHODH-like proteins from Mucorales and dematiaceous mould species.PloS one · 2023Article
- An update on the development of novel antifungal agents for eumycetoma.Frontiers in pharmacology · 2023Review
- Article
- Resistance profiling ofEmerging microbes & infections · 2022Article
- Article
- Pharmacodynamics, Mechanisms of Action and Resistance, and Spectrum of Activity of New Antifungal Agents.Journal of fungi (Basel, Switzerland) · 2022Review
- Screening the pandemic response box identified benzimidazole carbamates, Olorofim and ravuconazole as promising drug candidates for the treatment of eumycetoma.PLoS neglected tropical diseases · 2022Article
- Olorofim Effectively Eradicates DermatophytesAntimicrobial agents and chemotherapy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesEumycetoma is currently treated with a combination of itraconazole therapy and surgery, with limited success. Recently, olorofim, the lead candidate of the orotomides, a novel class of antifungal agents, entered a Phase II trial for the treatment of invasive fungal infections. Here we determined the activity of olorofim against Madurella mycetomatis, the main causative agent of eumycetoma.
methodsActivity of olorofim against M. mycetomatis was determined by in silico comparison of the target gene, dihydroorotate dehydrogenase (DHODH), and in vitro susceptibility testing. We also investigated the in vitro interaction between olorofim and itraconazole against M. mycetomatis.
resultsM. mycetomatis and Aspergillus fumigatus share six out of seven predicted binding residues in their DHODH DNA sequence, predicting susceptibility to olorofim. Olorofim demonstrated excellent potency against M. mycetomatis in vivo with MICs ranging from 0.004 to 0.125 mg/L and an MIC90 of 0.063 mg/L. Olorofim MICs were mostly one dilution step lower than the itraconazole MICs. In vitro interaction studies demonstrated that olorofim and itraconazole work indifferently when combined.
conclusionsWe demonstrated olorofim has potent in vitro activity against M. mycetomatis and should be further evaluated in vivo as a treatment option for this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.